

The neural basis of stop-signal inhibition in healthy individuals and in schizophrenia patients

Matthew Edward Hughes
BSc(Psyc)(Hons)

Submitted to the University of Newcastle, October 2009, in fulfillment of the
degree of Doctor of Philosophy

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying subject to the provisions of the Copyright Act 1968.

Matthew Edward Hughes

Acknowledgements

Thanks must first go to my primary supervisor, Professor Pat Michie, for her inspiration and unwavering support, encouragement and confidence in me during this process, and to my secondary supervisor, Dr Ross Fulham for his assistance and conversations regarding data analysis, which I have found invaluable. I would also like to thank a former supervisor, Dr Bill Budd, and Dr Patrick Johnson, for their assistance and friendship (and cigarettes!) that I have enjoyed throughout.

Acknowledgements and thanks must also go to the many others who were integral to the studies detailed here, notably the Schizophrenia Research Institute (SRI) for supporting this work financially, the staff at Hunter Imaging (John Hunter Hospital, Newcastle) particularly Gary O’Conner and Steve Hudson for their assistance with data acquisition, and to Gavin Cooper at the University of Newcastle for programming the experiments.

This process has been made considerably easier by my network of family and friends, who have supported me throughout, especially my mother Vicki, father Robert and his partner Kerry, and my brothers Andrew and Luke without whom I would never have made it. Additionally, I would like to thank my oldest friends, especially Fraser, Robert, Drew, Colin and Trent for their support and good humour. And to my more recently acquired friends from the various labs I have worked and studied in, in particular Alynna, Vanessa, Juanita, Rowena and Sharna for all the conversation and joking around. Special thanks must go to Kathryn for her support, friendship, yoga sessions, tennis games and general fun – high times indeed! Finally, I would like to thank Christina for her love and support during the final stages of writing, and for ignoring my innumerable foibles.

Table of Contents

LIST OF FIGURES	VII
LIST OF TABLES	IX
GLOSSARY OF ABBREVIATIONS	XIV
ABSTRACT	XVI
CHAPTER 1: EXECUTIVE CONTROL	1
1.1. Control of cognition	1
1.1.1. Introduction	1
1.1.2 Control and the executive system	1
1.1.3 Definition of executive control	2
1.1.4 Roles and types of executive functions	3
1.1.5 Inhibition as a core feature of cognition	4
1.2. Behavioural inhibition paradigms	5
1.2.1. Behavioural inhibition	5
1.2.2. Go/No-go paradigms	8
1.2.3 The stop-signal paradigm	9
1.2.4 The race model	11
1.2.5 Estimating SSRT	14
Average SSRT	15
SSRT at the mean of the inhibition function	15
SSRT at the median of the inhibition function	15
1.2.6 Inhibition functions	16
1.2.7 Caveats to stop-signal inhibition indices	17
1.2.8 Appropriate setting of stop-signal delays	17
CHAPTER 2: THE FUNCTIONAL NEUROANATOMY OF BEHAVIOUR	19
2.1. Cortico-basal ganglia-thalamocortical pathways	19
2.1.1. Introduction	19
2.1.2. Cortico-basal ganglia-thalamo-cortical circuitry	19
2.1.3. Direct, indirect and hyperdirect cortico-basal ganglia-thalamocortical pathways	23
2.2. The functional neuroanatomy engaged during stop-signal inhibition	26
2.2.1. Overview	26
2.2.2. Rodent lesion evidence	28
2.2.3. Human lesion and TMS evidence	32
2.2.4. Human neuroimaging evidence	34
2.2.5. Stopping in Parkinson's Disease	36
2.2.6. ERPs elicited during stop-signal inhibition	39
2.3.1 Outstanding issues and present studies	47
CHAPTER 3: EXPERIMENT 1	50

3.1. Introduction	53
3.2. Methods.....	55
3.2.1. Participants and Procedures.....	55
3.2.2. Tasks and Stimuli	56
Stop-signal task: fMRI acquisition	56
Stop-signal task: Inhibition function.....	58
MR image acquisition.....	59
MR image pre-processing.....	59
Data Analysis: Behavioural data.....	59
Data Analysis: MRI data	60
Region of interest (ROI) analyses.....	61
3.3. Results	62
3.3.1. Behavioural data: fMRI session	62
Inhibition function data.....	63
3.3.2. Functional brain activation	63
Relationship between performance measures and functional brain activation	69
Small volume correction (SVC) analyses	69
3.4. Discussion.....	70
3.4.1. Behavioural data	70
3.4.2. Whole brain activation	71
Right inferior frontal gyrus.....	71
ACC.....	73
PreSMA	74
Right inferior parietal lobe.....	75
Cerebellum	75
3.4.3. Conclusion.....	77
 CHAPTER 4: EXPERIMENT 2.....	 79
4.1 Introduction	79
4.2 Methods.....	87
4.2.1. Participants and Procedures.....	87
4.2.2. Tasks and stimuli.....	87
Behavioural variables	89
Stimulus presentation	91
4.2.3. fMRI session.....	92
Participants	92
MR image acquisition.....	92
MR image pre-processing.....	92
Modeling: First level analyses	93
Group level analyses.....	94
Determining functional neuroanatomy	94
Region of interest (ROI) analyses.....	94
4.2.4. ERP session	95
Participants	95
EEG data recording	95
ERP data preprocessing	96
ERP trial averaging.....	96
ADJAR correction procedure for stop-signal task group average waveforms.....	96
Measurement of components from Stop and Stop Failure ERP waveforms.....	97
4.2.5 Correlation of Stop>Go contrasts with Stop related components.....	98

4.3. Results	98
4.3.1. fMRI session.....	98
4.3.1.1 Behavioural data.....	98
Reaction time (RT) data.....	98
Pre- and Post- event RT differences	99
Stop-signal trial data	100
4.3.1.2. fMRI data	101
Stops > Baseline	101
Simple correlation: SSRT and Stops > Baseline.....	102
Stop Failures > Baseline	106
Small volume correction (SVC) with a priori ROIs	108
Stops > Stop Failures.....	110
Stop Failures > Stops.....	112
ROI analyses: Analysis of parameter estimates	113
4.3.3. ERP session	116
4.3.3.1. Behavioural data	116
RT data	116
Pre- and Post- event RT differences	117
Stop-signal trial data	119
4.3.3.2. Go ERPs	119
4.3.3.3. Stop-signal ERPs	121
Other features of stop-signal ERPs.....	124
Central features of stop-signal ERPs	124
Auditory evoked N1: average waveform analyses	125
Stop-signal N1 latency.....	126
Stop-signal N1 Amplitude	126
Mean Stop-signal N2 amplitude	127
Stop-signal P3.....	128
Stop-signal P3 peak latency.....	129
Stop-signal P3 peak amplitude	130
Stop-signal P3 mean amplitudes (170 – 400 ms).....	130
Relationships between peak measures and stopping indices	131
4.3.3.4. Comparison of fMRI and ERP behavioural data	134
4.3.3.5. Correlation of Stop>Go contrasts with Stop related ERP measures	135
4.4. Discussion.....	135
4.4.1. Basic behavioural findings	135
4.4.2. fMRI findings	137
4.4.3.ERP findings.....	144
ADJAR efficacy	145
Stop signals elicit N1 and P3 potentials.....	145
4.4.4. Integration of fMRI and ERP findings	150
4.4.5. Conclusions	151
 CHAPTER 5: A BRIEF INTRODUCTION TO SCHIZOPHRENIA.....	153
 5.1. What is schizophrenia?	153
5.1.1. Introduction	153
5.1.2. Prevalence and incidence.....	154
5.1.3. Diagnostics	154
Symptomatology.....	154
Positive symptoms	156
Negative Symptoms.....	157
Diagnosis	158
5.2. Underlying causes of schizophrenia	158

5.2.1. Theories	158
5.2.2. Neurotransmitter systems and schizophrenia	160
The role of dopamine in schizophrenia	160
Dopaminergic pathways and antipsychotics	161
The role of glutamate in schizophrenia	166
5.3. Neuropsychological functioning in schizophrenia	168
5.3.1. Neuropsychological measures as diagnostic criteria	168
5.3.2. Neuropsychological impairment in schizophrenia	169
5.3.3. Executive functions, attention and memory impairments in schizophrenia	170
5.3.4. Some types of executive functions	172
5.3.5. What is probed during executive function tasks?	174
5.3.6. Performance requirements for executive function tasks	177
5.4. Behavioural inhibition as a discrete impairment in schizophrenia	178
5.4.1. Behavioural findings	178
5.4.2. Further evidence for response inhibition impairments in schizophrenia	180
5.4.3. Go/No-go evidence	181
5.4.4. ERP evidence	181
5.4.5. Neuroimaging evidence	183
5.5. Stop-signal evidence	186
5.5.1. Studies of stop-signal inhibition	186
5.5.2. Stopping in at-risk groups	186
5.5.3. Stopping in patients with a diagnosis of schizophrenia	188
5.5.4. Neuroimaging evidence	189
 CHAPTER 6: EXPERIMENT 3	 191
6.1. Introduction	191
6.2. Method	194
6.2.1. Research overview	194
6.2.2. Participants	194
Patient medication details and symptom ratings	195
6.2.3. Tasks and stimuli	196
Stimulus presentation	198
6.2.4. Behavioural variables	198
6.2.5. fMRI data	199
MR image acquisition	199
MR image pre-processing	199
Identifying ‘bad scans’	200
Modeling: First level analyses	200
Modeling: Second level analyses	201
Small volume correction (SVC) analyses	202
6.2.5. ERP data	202
EEG data recording	202
ERP data preprocessing	203
ERP trial averaging	203
ADJAR correction and Group averaging procedure for stop-signal group average waveforms	203
Component measures analyses for Go, Stop and Stop Failure waveforms	203
Integration of fMRI and ERP data	204
Latency and amplitude measures of Stop-N1, Stop-P3 and the Stop P3-N1 latency were correlated with Stops > Go contrast maps and explored in an SVC analysis using a priori ROIs outlined previously. Additionally, the mean of a potential identified in the N2 latency range in Stop Failure ERPs for both	

groups was correlated with Stop Failure > Go contrast maps for each group separately, testing for a negative relationship. This data was (post-hoc) explored by application of an ACC ROI constructed from AAL maps in an SVC analysis.204

6.3. Results	204
6.3.1. Trial type proportions for fMRI and ERP sessions	204
6.3.2. fMRI session	206
6.3.2.1. Age, gender and education	206
6.3.2.2. Behavioural data analyses	206
RT data	207
SSRT and SSD analyses	207
Errors	208
Pre and post-event RT analyses	208
Relationships between behavioural variables and symptom profiles	210
6.3.2.3. fMRI data	210
Go > Baseline: one-sample t-tests	210
Go > Baseline: Matched sample t-tests	210
Stops > Go contrast: One sample t-tests	212
Matched samples t-tests of Stop > Go contrast	216
Number of activated voxels in Go > Stops and Stops > Go contrasts for patient and controls groups	220
Stop Failures > Go: One sample t-tests	220
Matched sample t-tests	224
Simple correlation: SSRT and Stops > Go	229
6.3.3. ERP session	232
6.3.3.1. Age and education	232
6.3.3.2. Behavioural data analyses	233
RT data	233
Error analyses	233
SSD and SSRT	233
Relationships between behavioural variables and symptom profiles	234
Pre and post event RTs differences	234
6.3.3.3. Go stimulus ERP analyses	235
Go-N1 data	237
Peak Go-N1 amplitude and latency analyses	238
Parietal sites: Go-N1 peak amplitude	238
Parietal sites: Go-N1 peak latency	238
Mean Go-N1 amplitude analysis	238
Scalp topography analysis: mean Go-N1 amplitudes	238
Peak Go-P3 amplitude and latency analyses	239
Parietal sites: Go-P3 peak amplitude	239
Parietal sites: Go-P3 peak latency	240
Scalp topography analysis: mean Go-P3 amplitudes	240
6.3.3.4. Stop and Stop Failure ADJAR correction waveforms	240
6.3.3.5. Stop-signal ERP analyses	242
Auditory evoked N1: average waveform analyses	245
Stop-signal N1 peak latency and amplitude measures: At Cz only	246
Stop-signal N1 peak amplitude and latency measures: Across fronto-central sites	246
Inter-relationships between N1 measures, age and symptomatology	248
Mean N2 amplitude measures	250
P3 peak amplitude and latency measures	250
Latency measures	250
Peak amplitude analyses	251
Mean amplitudes: Scalp topography analysis (Group x Hand x Inhibition x AP x Laterality ANOVA)	252
Relationship between stop-signal P3 measures and symptomatology	253
Relationships between SSRT and ERP amplitude and latency measures	253

Relationships between ERP measures and Stops>Go contrasts	253
6.3.4. Between session behavioural analyses	254
6.4. Discussion.....	255
6.4.1. Overview	255
6.4.2. Behavioural Data	256
SSRT	256
Pre and post event RTs	260
6.4.3. fMRI data	261
Stopping data	261
Go data.....	263
6.4.4. ERP data	264
ADJAR efficacy	264
Go and stop-signal waveforms	265
N1 findings	266
Stop-signal N1 modulation	267
N1 Latency	270
P3 findings.....	270
N2 findings	273
 CHAPTER 7: DISCUSSION AND CONCLUSIONS.....	 275
7.1 Introduction	275
7.2 Key findings	275
7.3 Neuroimaging data	277
7.4 Electrophysiological data	280
7.5 Stopping in patients with schizophrenia	282
7.6 How this thesis has added to the literature	284
7.7 Limitations of studies	286
7.8 Future directions	288
 REFERENCES	 290

List of Figures

Figure 1.1. Go and No-go trials in a simple Go/No-go variant.....	9
Figure 1.2. Stop-signal paradigm trial types.....	10
Figure 1.3. Models used to describe inhibition.....	12
Figure 1.4: The race model (adapted from Logan & Cowan, 1984).....	13
Figure 2.01. The parallel cortico-basal ganglia-thalamo-cortical circuits (adapted from Alexander et al., 1986).....	20
Figure 2.02. The ‘direct’, ‘indirect’ and ‘hyperdirect’ cortico-basal ganglia-thalamocortical pathways (adapted from Nambu et al., 2002).	24
Figure 3.1. Brain activation revealed by the Stop vs. Go contrast slicing up through cerebellar and cerebral cortices from left to right and top to bottom.....	67
Figure 3.2. Correlation between Stop vs. Go contrast values in right inferior frontal gyrus ROI and average SSRT across delays.....	69
Figure 4.01. Stop-signal task trials.....	89
Figure 4.02. Regression of PI and SSRT.	101
Figure 4.03. Cortical activation for Stops > Baseline contrast (thresholding at $p < .001$, 10 contiguous voxels) with views of right hemisphere (left), superior midline (centre) and left hemisphere (right) activation.....	103
Figure 4.04. Brain areas in Stops > Baseline contrast maps showing significant positive correlations with SSRT (thresholding at $p < .01$, and 10 contiguous voxels).....	103
Figure 4.05. Negative correlation between Stops > Baseline contrast maps and SSRT (thresholding at $p < .01$, and 10 contiguous voxels), showing right hemisphere (on left), mid-line sagittal (middle), and left hemisphere (on right) views.....	106
Figure 4.06. Cortical activation for Stop Failures > Baseline contrast (thresholding was $p < .001$, 10 contiguous voxels) with views of the right hemisphere (left), superior midline (centre) and left hemisphere (right) activation.....	107
Figure 4.07. Brain regions showing significant activation in the contrast of Stops > Stop Failures (thresholding was $p < .01$, and 10 contiguous voxels).....	112
Figure 4.08. Scatterplots of mean parameter estimates against SSRT for ROIs that were significantly correlated with SSRT, in addition to the correlation of MFG parameter estimates and SSRT	115
Figure 4.09. Left and right hand grand average Go ERPs at frontal (F3, Fz, F4), central (C3, Cz, C4) and parietal sites (P3, Pz, P4).	120
Figure 4.10. Scalp correction waveforms estimated by the ADJAR procedure at midline and lateral frontal (F3,Fz,F4), central (C3,Cz,C4) and parietal sites (P3,Pz,P4) for left and right Stops and Stop Failures.	122
Figure 4.11. Plots of uncorrected stop-signal ERPs, ADJAR correction waveforms, and ADJAR corrected stop-signal ERPs at Cz for left and right hands.	123
Figure 4.12. Stop-signal ERPs for left and right hands.	125
Figure 4.13. Scatterplots depicting relationships observed between SSRT and left hand Stop-P3 amplitude (on left), and SSRT and right hand Stop-P3 (on right) at Fz.	132
Figure 4.14. Scatterplots of the difference between Stop-P3 and Stop-N1 peak latency and SSRT for left and right hands at Fz.....	133
Figure 6.01. Go > Baseline contrasts (right is right).....	212

Figure 6.02. Cortical activation for Stops > Go in control and patient groups.....	215
Figure 6.03. Subcortical and anterior cingulate (ACC) activation revealed in Stops > Go	216
Figure 6.04. Prefrontal and subcortical areas revealing greater activation in the controls > patients contrast above threshold activation	218
Figure 6.05. PFC activation surviving threshold ($p < .05$, 10 contiguous) when Stops > Go contrasts were compared for patients > controls.....	219
Figure 6.06. Within group activation for (A) controls (top panel views: right hemisphere cortex, superior cortical surface, and left hemisphere cortex), and (B) patients (bottom panel views: right hemisphere cortex, axial slice emphasizing STN activation,, and left hemisphere cortex).....	223
Figure 6.07. Control group activation shown by axial slices through the cortex for the Stops > Stop Failure contrast (thresholding was $p < .01$, 10 contiguous voxels).....	228
Figure 6.08. Left and right hand correct grand average Go ERPs for control and patient groups.....	236
Figure 6.09. Outcome from ADJAR correction procedure at Cz for (A) left hand, and (B) right hand, Stop and Stop Failure grand average ERP waveforms for control and patient groups.....	242
Figure 6.10. Left hand ADJAR corrected Stop and Stop Failure grand average ERP waveforms for control and patient groups.	244
Figure 6.11. Right hand ADJAR corrected Stop and Stop Failure grand average waveforms for control and patient groups.	245
Figure 6.12. Scatterplots of Stop-N1 latency and total SANS scores for left and right hands at Fz (top panel) and Cz (bottom panel).	249

List of Tables

Table 3.1.....	62
Behavioural Data obtained from Scanning Sessions. RT means displayed are calculated from median RTs from individual participants.....	62
Table 3.2.....	63
Mean Stop-signal Delay (SSD) and Mean Probability of Inhibition (P(I)) at each delay. ..	63
Table 3.3.....	64
Group brain activation for the Stops > Passive contrast.	64
Table 3.4.....	65
Group brain activation for the Go > Passive contrast.	65
Table 3.5.....	68
Group Brain Activation Revealed in the Stop vs Go Contrast.....	68
Table 3.6.....	68
Non-parametric Group Brain Activation Revealed in the Stop vs Go Contrast.	68
Table 4.01.....	97
Latency ranges over which component measures were extracted for statistical analysis....	97
Table 4.02.....	99
Mean group data for behavioural indices (with standard deviations in parentheses) from fMRI sessions.....	99
Table 4.03.....	100
Group means of participant median pre and post event RTs in ms collapsed over left and right hands (with standard deviations in parenthesis).	100
Table 4.04.....	102
Activation table for Stops > Baseline (thresholding was $p < .001$, 10 contiguous voxels)	102
Table 4.05.....	104
Brain areas revealing positive SSRT correlated BOLD variance in Stops > Baseline contrasts (thresholding was $p < .01$, 10 contiguous voxels)	104
Table 4.06.....	105
Brain areas revealing negative SSRT correlated BOLD variance in Stops > Baseline contrasts (thresholding was $p < .01$, 10 contiguous voxels)	105

Table 4.07.....	107
Activation table for Stop Failures > Baseline (thresholding was $p < .001$, and 10 contiguous voxels).....	107
Table 4.08.....	109
Small volume correction (SVC) output for right hemisphere <i>a priori</i> regions of interest (ROIs).....	109
Table 4.09.....	111
Activation table for Stops > Stop Failures (thresholding was $p < .01$, and 10 contiguous voxels).....	111
Table 4.10.....	113
Activation table for Stop Failures > Stops (thresholding was $p < .01$, and 10 contiguous voxels).....	113
Table 4.11.....	114
Means and standard deviations of parameter estimates extracted in right hemisphere brain regions defined by AAL probability maps and their Pearson's correlation (r) with SSRT (one-tailed)	114
Table 4.12.....	115
Correlation matrix of parameter estimates extracted from <i>a priori</i> ROIs that were significantly correlated with SSRT, r (sig.)	115
Table 4.13.....	117
Mean scores on behavioural indices (with standard deviations in parentheses) from ERP sessions.....	117
Table 4.14.....	118
Group mean pre and post event RTs (with standard deviations in parentheses) collapsed over left and right hands.....	118
Table 4.15.....	127
Summary of group mean ($N = 12$, with standard deviation in parentheses) Stop-N1 and Stop Failure-N1 peak amplitude and latency measures of N1 (time window = 50 – 150 ms) at Fz and Cz for left and right hand events	127
Table 4.16.....	128

Summary of group mean (with standard deviation in parentheses) Stop and Stop Failure N2 mean amplitude measures (across the time window 180 – 320 ms) at midline electrodes averaged for left and right hand events (N = 14).....	128
Table 4.17.....	129
Summary of group mean (with standard deviation in parentheses) Stop and Stop Failure peak amplitude and latency measures of P3 (time window = 170 – 600 ms) at Fz, Cz and Pz for left and right hand events (N = 11).....	129
Table 4.18.....	131
Summary of group mean (with standard deviation in parentheses) Stop and Stop Failure P3 mean amplitude measures (across the time window 170 – 400 ms) at midline electrodes averaged for left and right hand events (N = 14).....	131
Table 6.01.....	195
Antipsychotic medication summary for the patient group.....	195
Table 6.02.....	196
Mean ratings (with standard deviations in parentheses) on SAPS and SANS sub-scales, total global scores for the patient group.....	196
Table 6.03.....	205
Mean numbers and proportions (with standard deviations in parentheses) of trial types by experimental session	205
Table 6.04.....	208
Left and right hand fMRI session behavioural data for patient and control groups	208
Table 6.05.....	209
Patient and control group median pre and post event RTs for left and right hands	209
Table 6.06.....	211
Brain areas surviving thresholding from matched samples t-tests, Controls > Patients and Patients > Controls, in a comparison of Go > Baseline contrast maps (thresholding was $p < .01$, and 10 contiguous voxels)	211
Table 6.07.....	213
Control group activation for Stops > Go contrast (thresholding was $p < .01$, and 10 contiguous voxels)	213
Table 6.08.....	214

Patient group activation for Stops > Go contrast (thresholding was $p < .01$, and 10 contiguous voxels)	214
Table 6.09.....	217
Areas surviving thresholding in a matched-samples t-test contrast testing differences in Stop > Go related activation for Controls > Patients	217
Table 6.10.....	219
Areas surviving thresholding in a matched-samples t-test contrast testing differences in Stop > Go related activation for Patients > Controls	219
Table 6.11.....	220
Total voxels surviving thresholding (at $p < .05$, 5 contiguous voxels) for left, right and combined Go > Stops and Stops > Go contrasts for patient and control groups	220
Table 6.12.....	221
Control group activation for Stop Failures > Go one sample t-test ($p < .01$, and 10 voxels)	221
Table 6.13.....	222
Patient group activation for Stop Failures > Go one-sample t-test ($p < .01$, and 10 voxels)	222
Table 6.14.....	224
Areas surviving thresholding in a matched-samples t-test contrast testing differences in Stop Failures > Go related activation for Controls > Patients.	224
Table 6.15.....	225
Areas surviving thresholding in a matched-samples t-test contrast testing differences in Stop Failures > Go related activation for Patients > Controls	225
Table 6.16.....	226
Control group activation for a repeated-measures t-test contrast of (Stops > Go) > (Stop Failures > Go; $p < .01$, and 10 voxels).....	226
Table 6.17.....	228
Control group activation for a repeated-measures t-test contrast of (Stop Failures > Go) > (Stops > Go; $p < .01$, and 10 voxels)	228
Table 6.18.....	229

Control group t-maps arising from the negative correlation of SSRT with Stops > Go contrast maps (thresholding was $p < .01$ and 10 contiguous voxels).....	229
Table 6.19.....	230
Patient group t-maps arising from the correlation of SSRT with Stops > Go contrast maps (thresholding was $p < .01$ and 10 contiguous voxels).....	230
Table 6.20.....	231
SVC analyses for control group Stops > Go and Stop Failures > Go contrast t-maps	231
Table 6.21.....	232
ERP session behavioural data (hand-wise) for patients and control groups	232
Table 6.22.....	235
Control and patient group pre and post event RTs for left and right hand events	235
Table 6.23.....	237
Group means at parietal sites P3 and P4 for Go-N1 peak amplitude and latency (controls = 11, patients = 9), and for mean Go-N1 amplitude (controls = 13, patients = 10)	237
Table 6.24.....	251
Group mean stop-signal P3 peak latency measures (in milliseconds, ms) for control (N = 12) and patient (N = 7) groups used in fronto-central midline electrode analysis. Standard deviations are in parentheses	251
Table 6.25.....	252
Group mean stop-signal P3 peak amplitude measures (in microvolts, μV) for control (N = 12) and patient (N = 7) groups used in fronto-central midline electrode analysis. Standard deviations are in parentheses	252

Glossary of abbreviations

AAL.....	automated anatomical labeling
ACC.....	anterior cingulate cortex
ADJAR.....	adjacent response technique
ADHD.....	attention deficit hyperactivity disorder
BA.....	Brodmann Area
BOLD.....	blood oxygenation level dependent
DBS.....	deep brain stimulation
DLPFC.....	dorsolateral prefrontal cortex
DSM.....	Diagnostic and Statistical Manual of Mental Disorders
EEG.....	electroencephalogram
EOS.....	early onset schizophrenia
EPI.....	echo-planar imaging
EPS.....	extra-pyramidal symptoms
ERP.....	event-related potential
FEF.....	frontal eye fields
fMRI.....	functional magnetic resonance imaging
FWHM.....	full width at the half-maximum
GABA.....	gamma amino butyric acid
GABAergic.....	using GABA as a neurotransmitter
GLM.....	general linear model
GoRT.....	median Go reaction time
GP.....	globus pallidus
GPe.....	globus pallidus (<i>pars externa</i> - external capsule)
GPI.....	globus pallidus (<i>pars interna</i> - internal capsule)
HRF.....	hemodynamic response function
IFG.....	inferior frontal gyrus
IPL.....	inferior parietal lobe
ISI.....	interstimulus interval
M1.....	primary motor cortex (or sensorimotor cortex)
MFG.....	middle frontal gyrus
MNI.....	Montreal Neurological Institute
MRT.....	median reaction time
NMDA.....	N-methyl D-aspartate
N1.....	first negative-going ERP component
N2.....	second negative-going ERP component
OCD.....	obsessive-compulsive disorder
OFC.....	orbital frontal cortex
PCP.....	phencyclidine
PET.....	positron emission tomography
PD.....	Parkinson's Disease
PI.....	probability of inhibition (also P(i))
PFC.....	prefrontal cortex
PMC.....	premotor cortex
PR.....	probability of responding (also P(r))

P3.....	third positive going ERP component
preSMA.....	pre-supplementary motor area (or anterior supplementary motor area)
ROI.....	region of interest
RTs.....	reaction times
SANS.....	scale for the assessment of negative symptoms
SAPS.....	scale for the assessment of positive symptoms
SFG.....	superior frontal gyrus
SMA.....	supplementary motor area
SNr.....	substantia nigra <i>pars reticulata</i>
SOA.....	stimulus onset asynchrony
SSD.....	stop-signal delay
SSRT.....	stop-signal reaction time
STN.....	subthalamic nucleus
STG.....	superior temporal gyrus
STR.....	striatum
SVC.....	small volume correction
Thal.....	thalamus
TMS.....	transcranial magnetic stimulation
VLFPFC.....	ventrolateral prefrontal cortex
VTA.....	ventral tegmental area
WCST.....	Wisconsin card sorting test
ZRFT.....	z relative finishing time

Abstract

The capacity to inhibit planned or on-going action enables individuals to flexibly control behaviour in response to changing task demands or a change in goals. This capacity, termed *response inhibition*, is a core function of the executive control system and is often studied in laboratory settings using the stop-signal paradigm, which was used for studying response inhibition throughout this thesis. The stop-signal paradigm (Logan & Cowan, 1984) is increasingly being used by research groups to study response inhibition largely due to the indices of behavioural control afforded by stop-signal procedures, notably the speed of response inhibition processes and the capacity to trigger these processes.

Lesion, transcranial magnetic stimulation and neuroimaging experiments have linked stopping to activity in the right inferior frontal gyrus (IFG), and some evidence indicates a role for the subthalamic nucleus (STN). These brain areas are thought to form a network which acts by suppressing thalamo-cortical output to motor cortex. Event-related potential studies have linked stopping to amplitude enhancement of an N1-P3 complex during successful inhibition trials compared to unsuccessful inhibition trials.

The primary aim of this thesis was to investigate the spatio-temporal dynamics of stop-signal inhibition in healthy individuals using electrophysiological and neuroimaging methods, and secondly, to investigate the neural basis of impaired stopping in patients with a diagnosis of schizophrenia – the first of its kind using the stop-signal paradigm. Several previous behavioural studies have reported slowed stop-signal response inhibition processes in patients with schizophrenia, but an impaired capacity to trigger response inhibition processes has also been reported.

In each of the three neuroimaging studies detailed herein, stopping was related to activation in right IFG and STN, and in one study a model for the difficulty of inhibition was proposed, which predicted activity in this network. Consistent with previous reports, stopping processes in patients with schizophrenia were slower compared to controls, and right IFG and STN were uniquely underactivated in the patient group. Additionally, one study revealed a link between response inhibition speed and both Stop-P3 amplitude, and the latency difference between N1 and P3 potential peaks elicited on stop-signal trials.